Steve Bain, MD

Steve Bain, MD

Professor of Medicine (Diabetes)
College of Medicine
Swansea University
Swansea, UK

Related Videos

Do you have any explanation for why liraglutide was associated a lower risk of hypoglycemia than in the control arm of the LEADER trial? Video

Do you have any explanation for why liraglutide was associated a lower risk of hypoglycemia than in the control arm of the LEADER trial?

Do you have any explanation for why liraglutide was associated a lower risk of hypoglycemia than in the control arm of the LEADER trial?

Based on the results of the LEADER trial, where would you position liraglutide in the ADA/EASD sequencing algorithm for antidiabetic agents? Video

Based on the results of the LEADER trial, where would you position liraglutide in the ADA/EASD sequencing algorithm for antidiabetic agents?

Based on the results of the LEADER trial, where would you position liraglutide in the ADA/EASD sequencing algorithm for antidiabetic agents?

How do you interpret the LEADER results showing reduction in microvascular events as well as macrovascular events. What drove these reductions? Video

How do you interpret the LEADER results showing reduction in microvascular events as well as macrovascular events. What drove these reductions?

How do you interpret the LEADER results showing reduction in microvascular events as well as macrovascular events. What drove these reductions?

Based on LEADER, is there an ideal age group for liraglutide? Should it be used in younger and older patients? What dose should we be trying to achieve? What is the toleration profile? Video

Based on LEADER, is there an ideal age group for liraglutide? Should it be used in younger and older patients? What dose should we be trying to achieve? What is the toleration profile?

Based on LEADER, is there an ideal age group for liraglutide? Should it be used in younger and older patients? What dose should we be trying to achieve? What is the toleration profile?

Which patient subgroups, based on the LEADER trial, are most likely to benefit from liraglutide therapy? High risk? Low risk? Both? At what point in the natural history of T2D? Early? Late? Both? Video

Which patient subgroups, based on the LEADER trial, are most likely to benefit from liraglutide therapy? High risk? Low risk? Both? At what point in the natural history of T2D? Early? Late? Both?

Which patient subgroups, based on the LEADER trial, are most likely to benefit from liraglutide therapy? High risk? Low risk? Both? At what point in the natural history of T2D? Early? Late? Both?

Which results from LEADER are the most transformative as far as CV risk reduction in T2D, and what might the implications be about the mechanism by which liraglutide reduces CV events? Video

Which results from LEADER are the most transformative as far as CV risk reduction in T2D, and what might the implications be about the mechanism by which liraglutide reduces CV events?

Which results from the LEADER trial do you consider to be most transformative as far as our approach to CV risk reduction in T2D, and what might the implications be about the mechanism by which liraglutide reduces CV events?